Merged company will not create new global headquarters in the New York/New Jersey region as previously announced (1"The Pink Sheet" Jan. 24, p. 18). U.S. operations will instead be based out of existing companies' headquarters in Research Triangle Park, N.C. (Glaxo Wellcome) and Philadelphia (SmithKline Beecham). Sales and marketing components in the U.S. will also remain separate during the first phases of the merger process (2"The Pink Sheet" Feb. 7, p. 19)
You may also be interested in...
The U.S. pharmaceutical operations of Glaxo Wellcome and SmithKline Beecham will not be combined immediately as part of the merger integration process.
Glaxo SmithKline's U.S. management team is to be worked out during the merger integration process between the two companies.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011